NEW YORK, Dec 22 - Deltagen said Friday that it has signed Pfizer as the second licensee to its DeltaBase gene function database.
Under the terms of the agreement, Pfizer will have non-exclusive access to in vivo mammalian gene function information on 750 genes in DeltaBase, as well as access to corresponding DeltaBase intellectual property rights.
The initial term of the agreement is three years, through June 30, 2003, with the option to extend the term for two additional years. Pfizer will have access to 250 genes per year.
Pfizer elected to license all previous data releases under DeltaBase. Deltagen will receive $15 million in license access fees, with up to $25 million possible with term extensions. Other financial terms of the agreement were not disclosed.
“We believe that DeltaBase will become an integral part of the pharmaceutical R&D process by providing researchers with the capacity to translate raw genomic sequence into information on the function, disease relevance and potential commercial value of a particular gene," said Bill Matthews, president and CEO of Deltagen, in a statement.
DeltaBase contains functional and phenotypic information for genes that have been chosen for their ability to be useful targets for drug discovery.
Deltagen signed Glaxo Wellcome as its first DeltaBase subscriber in September under similar terms.